The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1563
ISSUE1563
January 14, 2019
Dupilumab (Dupixent) for Asthma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Dupilumab (Dupixent) for Asthma
January 14, 2019 (Issue: 1563)
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.